HIK Hikma Pharmaceuticals Plc

RNS Number:2270I
Hikma Pharmaceuticals Plc
21 November 2007


                      Update on lisinopril contract

London, 21 November 2007 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
("Hikma") announces that it is still  awaiting the re-issuance of the
solicitation for the supply of lisinopril from the US Department of Veterans
Affairs.  Once this solicitation is issued, Hikma intends to participate as
normal in the bidding process.  Hikma continues to  supply lisinopril under its
existing contract with the Department of Veterans Affairs, which runs through to
20  December 2007.


                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC                               +44 20 7399 2670
Susan Ringdal, Investor Relations Director

Brunswick Group LLP                                     +44 20 7404 5959
Jon Coles / Justine McIlroy / Alex Tweed


Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products.  Hikma operates through three
businesses: "Branded", "Injectables" and "Generics", based principally in the
Middle East and North Africa ("MENA"), where it is a market leader and sells
across 18 countries, the United States and Europe.  In the year ended 31
December 2006, Hikma achieved revenues of $317 million (2005: $262 million) and
profit attributable to shareholders was $55 million (2005: $44 million).  At 31
December 2006, the Group had over 2,400 employees.  For news and other
information, please visit www.hikma.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
MSCEASFFALKXFFE

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024